Kindeva Drug Delivery has announced the appointment of Denis Johnson as Chief Operating Officer. Johnson was most recently Head of Global Manufacturing at Biogen and had previously served in executive roles at Catalent Pharma Solutions and Boston Scientific. The company noted that one of Johnson’s focuses will be on Kindeva’s efforts around transitioning MDIs to LGWP propellants.
Johnson commented, “Kindeva’s commitment to more patient-centric, sustainable drug delivery systems as well as continued growth, especially over the past year, is exciting. I’m excited to join the Kindeva team to drive continued operational excellence and implement strategies that ensure the timely delivery of life-changing medications to patients worldwide.”
Kindeva CEO Milton Boyer said, “Denis’ extensive experience in the CDMO space and track record of driving operational excellence will be invaluable as Kindeva continues to expand and innovate in the drug-delivery space. His strong leadership skills and deep understanding of the market will support Kindeva specifically in working toward introducing the first 152a commercial green propellant line to the market — clinical supply is already available and by 2025, we plan to introduce some of the first-ever products using this alternative propellant to the market. Additionally, Denis will focus on optimizing manufacturing processes, enhancing operational efficiencies, ensuring the highest level of quality and compliance across all facilities, and more.”
Read the Kindeva Drug Delivery press release.
